144 related articles for article (PubMed ID: 10221467)
1. Constrictive pericarditis and pleuropulmonary disease linked to ergot dopamine agonist therapy (cabergoline) for Parkinson's disease.
Ling LH; Ahlskog JE; Munger TM; Limper AH; Oh JK
Mayo Clin Proc; 1999 Apr; 74(4):371-5. PubMed ID: 10221467
[TBL] [Abstract][Full Text] [Related]
2. Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease.
Townsend M; MacIver DH
Heart; 2004 Aug; 90(8):e47. PubMed ID: 15253989
[TBL] [Abstract][Full Text] [Related]
3. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
Antonini A; Poewe W
Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
[TBL] [Abstract][Full Text] [Related]
4. [Constrictive pericarditis caused by carbergoline].
Hjortshøj SP; Poulsen SH; Andreasen JJ
Ugeskr Laeger; 2006 Jun; 168(26-32):2572-3. PubMed ID: 16824416
[TBL] [Abstract][Full Text] [Related]
5. Pleuropulmonary disease associated with dopamine agonist therapy.
Bhatt MH; Keenan SP; Fleetham JA; Calne DB
Ann Neurol; 1991 Oct; 30(4):613-6. PubMed ID: 1686385
[TBL] [Abstract][Full Text] [Related]
6. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
7. A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia.
Löndahl M; Nilsson A; Lindgren H; Katzman P
Eur J Endocrinol; 2008 Apr; 158(4):583-5. PubMed ID: 18362307
[TBL] [Abstract][Full Text] [Related]
8. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
[TBL] [Abstract][Full Text] [Related]
9. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Marco AD; Appiah-Kubi LS; Chaudhuri KR
Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
[TBL] [Abstract][Full Text] [Related]
10. Pleuropulmonary disease during bromocriptine treatment of Parkinson's disease.
McElvaney NG; Wilcox PG; Churg A; Fleetham JA
Arch Intern Med; 1988 Oct; 148(10):2231-6. PubMed ID: 3178380
[TBL] [Abstract][Full Text] [Related]
11. Pleuropulmonary changes during treatment of Parkinson's disease with a long-acting ergot derivative, cabergoline.
Frans E; Dom R; Demedts M
Eur Respir J; 1992 Feb; 5(2):263-5. PubMed ID: 1348483
[TBL] [Abstract][Full Text] [Related]
12. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists.
Andersohn F; Garbe E
Mov Disord; 2009 Jan; 24(1):129-33. PubMed ID: 19170199
[TBL] [Abstract][Full Text] [Related]
13. The older Parkinson's disease drugs pergolide and cabergoline have been linked to heart problems. Are there any new Parkinson's drugs which are safer for patients with heart risks?
Heart Advis; 2009 Aug; 12(8):8. PubMed ID: 21188763
[No Abstract] [Full Text] [Related]
14. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy.
Pullan PT
Intern Med J; 2009 Apr; 39(4):213-5. PubMed ID: 19402858
[No Abstract] [Full Text] [Related]
15. [Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline].
Sato T; Kikuchi A; Onoue N; Hiramoto T; Oumi M; Onodera J
Rinsho Shinkeigaku; 2008 Jul; 48(7):486-91. PubMed ID: 18717182
[TBL] [Abstract][Full Text] [Related]
16. [Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients].
Steffensen C; Mægbæk ML; Laurberg P; Andersen M; Kistorp C; Nørrelund H; Dal J; Jørgensen JO
Ugeskr Laeger; 2014 Jan; 176(1):58-60. PubMed ID: 24629610
[TBL] [Abstract][Full Text] [Related]
17. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease.
Tintner R; Manian P; Gauthier P; Jankovic J
Arch Neurol; 2005 Aug; 62(8):1290-5. PubMed ID: 16087771
[TBL] [Abstract][Full Text] [Related]
18. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis.
Hofmann C; Penner U; Dorow R; Pertz HH; Jähnichen S; Horowski R; Latté KP; Palla D; Schurad B
Clin Neuropharmacol; 2006; 29(2):80-6. PubMed ID: 16614540
[TBL] [Abstract][Full Text] [Related]
19. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
[TBL] [Abstract][Full Text] [Related]
20. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
[No Abstract] [Full Text] [Related]
[Next] [New Search]
